Peringatan Keamanan

Acute oral toxicity (LD50): 1271 mg/kg (rat) MSDS

Overdose information

Fluconazole overdoses have been associated with hallucination and paranoia, sometimes in combination.L11043 In cases of overdose, employ supportive treatment. Gastric lavage may be necessary.L11043 Other modalities such as forced diuresis or hemodialysis may also be used.L11043

A note on liver toxicity

The FDA label warns that this drug carries a risk of hepatotoxicity. Rare but serious cases of serious hepatic toxicity have been reported, especially in patients with serious underlying medical conditions using fluconazole. This group of patients has an increased risk of fatality when using fluconazole.L11043 In patients with existing liver dysfunction, use caution during fluconazole therapy. Those who are found to have abnormal liver function tests during therapy should be carefully monitored for the development of increasingly severe injury to the liver. Fluconazole should be stopped if its use is likely to be the underlying cause of liver injury, and medical attention should be sought.L11043,L6505 Fluconazole induced hepatotoxicity is usually reversible.L11043

Carcinogenesis, mutagenesis, and impairment of fertility

Fluconazole demonstrated no evidence of carcinogenic risk in mice and rats treated orally for 24 months at doses equivalent to approximately 2-7 time the recommended human dose). Male rats given fluconazole at doses equivalent to supratherapeutic human doses showed an increased incidence of hepatocellular adenomas. Cytogenetic studies in vivo and in vitro demonstrated no sign of chromosomal mutation. The significance of these findings for humans is unknown.L11043

Use in pregnancy

There are no sufficient and well-controlled studies of fluconazole use in pregnant women. Available human data do not show an increased risk of congenital anomalies after pregnant women were treated with standard doses (<200 mg/day) of fluconazole, either in a single dose or multiple doses in the first trimester did not appear to impact the fetus negatively.L11043 Several case reports describe rare but striking congenital anomalies observed in infants who were exposed to fluconazole at high doses reaching 400-800 mg/day, primarily in the first trimester of pregnancy. Similar findings were observed in animal studies. If this drug is administered during pregnancy, or if the patient becomes pregnant while taking fluconazole, the risk should be discussed thoroughly.L11043

Use in nursing

Fluconazole is secreted in breastmilk at high concentrations. Exercise caution if this drug is used during nursing.L11043

Fluconazole

DB00196

small molecule approved investigational

Deskripsi

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.A174325

Struktur Molekul 2D

Berat 306.2708
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The terminal elimination half-life in the plasma is approximately 30 hours (range: 20-50 hours) after oral administration.[L11043] The long plasma elimination half-life supports a single-dose therapy for vaginal candidiasis, once daily and once weekly dosing for other indications.[L11034] Patients with renal failure may require dosage adjustment, and half-life can be significantly increased in these patients.[A178792]
Volume Distribusi The apparent volume of distribution is said to be similar to the volume of distribution of total body water.[L11043] One clinical study of healthy volunteers administered 50 mg/kg of fluconazole was 39L, based on a body weight of 60kg.[A178792] Fluconazole shows substantial penetration in many body fluids, which is a property that renders it an ideal treatment for systemic fungal infections, especially when administered over a longer time.[A178792,L11043] Fluconazole is found in high concentrations in the stratum corneum and dermis-epidermis of skin, in addition to eccrine sweat. Fluconazole is found to accumulate especially well in the stratum corneum, which is beneficial in superficial fungal infections.[L11034] Saliva and sputum concentrations of fluconazole are found to be similar to the plasma concentrations.[L6505] In patients diagnosed with fungal meningitis, fluconazole CSF (cerebrospinal fluid) levels are measured to be about 80% of the corresponding plasma levels. Therefore, fluconazole crosses the blood-brain barrier.[L11034] The meninges are increasingly permeable to fluconazole in states of inflammation, facilitating treatment in meningitis.[A178801]
Klirens (Clearance) This drug is mainly eliminated by the kidneys and the mean body clearance in adults is reported to be 0.23 mL/min/kg.[L11043] One clinical study of healthy subjects showed total clearance of 19.5 ± 4.7 mL/min and renal clearance of 14.7 ± 3.7 mL/min (1.17 ± 0.28 and 0.88 ± 0.22 L/h).[A178792] Clearance in the pediatric population varies according to age, as does clearance in patients with renal failure.[L11043]

Absorpsi

The pharmacokinetic properties of fluconazole are comparable after administration by the intravenous (IV) and oral (PO) routes. In healthy volunteers, the bioavailability of orally administered fluconazole is measured to be above 90%.L11043 It is extensively absorbed in the gastrointestinal tract when an oral dose is taken.A178813 Oral absorption is not affected by food intake with fluconazole but may increase the time until the maximum concentration is reached.L11034,A178792 Tmax (or the time taken to achieve the maximum concentration) in one clinical study of healthy patients receiving 50 mg/kg of fluconazole was 3 hours.A178792 Peak plasma concentrations (Cmax) in fasting and healthy volunteers occur between 1-2 hours post-dose.L11043 Steady-state concentrations are achieved within 5 to 10 days after oral doses of 50-400 mg administered once daily. Administration of a loading dose on the first day of fluconazole treatment, or twice the usual daily dose, leads to plasma concentrations close to steady-state by the second day.L11043 Mean AUC (area under the curve) was 20.3 in healthy volunteers receiving 25 mg of fluconazole.A178792 A note on the capsule and powder form and malabsorption syndromes The capsule forms of fluconazole often contain lactose and should not be administered with hereditary galactose intolerance, Lapp lactase enzyme deficiency, or malabsorption of glucose/galactose.L11043 The powder form, used for the oral suspension, lists sucrose as an ingredient and should not be used in patients who have been diagnosed with fructose, glucose/galactose malabsorption, and sucrase-isomaltase enzyme deficiency.L11043

Metabolisme

Fluconazole is metabolized minimally in the liver. Fluconazole is an inhibitor of CYP2C9, CYP3A4 and CYP2C19.L11034,L11043 Two metabolites were detected in the urine of healthy volunteers taking a 50 mg radiolabeled dose of fluconazole; a glucuronidated metabolite on the hydroxyl moiety (6.5%) and a fluconazole N-oxide metabolite (2%).A178813 The same study indicated that no signs of metabolic cleavage of fluconazole were observed, suggesting a difference in metabolism when compared to other agents in the same drug class, which are heavily metabolized in the liver.A178813,A178834

Rute Eliminasi

In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose measured in the urine as unchanged drug.L11043 About 11% of the dose is excreted in the urine as metabolites.L11043. A study of a 50mg radiolabeled dose of fluconazole revealed that 93.3% of the dose was found excreted in the urine.A178813 A note on renal failure The pharmacokinetics of fluconazole are significantly affected by renal dysfunction. The dose of fluconazole may need to be reduced in patients with decreased renal function. A 3-hour hemodialysis treatment lowers plasma fluconazole concentrations by about 50%.L11043

Interaksi Makanan

1 Data
  • 1. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1712 Data
Afatinib The serum concentration of Afatinib can be increased when it is combined with Fluconazole.
Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Fluconazole.
Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Fluconazole.
Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Fluconazole.
Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.
Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Fluconazole.
Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Fluconazole.
Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Fluconazole.
Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Fluconazole.
Silodosin The excretion of Silodosin can be decreased when combined with Fluconazole.
Topotecan The serum concentration of Topotecan can be increased when it is combined with Fluconazole.
Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Fluconazole.
Amitriptyline Amitriptyline may increase the QTc-prolonging activities of Fluconazole.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Fluconazole.
Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Fluconazole.
Citalopram The risk or severity of QTc prolongation and serotonin syndrome can be increased when Fluconazole is combined with Citalopram.
Didanosine Didanosine can cause a decrease in the absorption of Fluconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Fluconazole.
Everolimus The metabolism of Everolimus can be decreased when combined with Fluconazole.
Flibanserin The metabolism of Flibanserin can be decreased when combined with Fluconazole.
Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Fluconazole.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Fluconazole.
Ivabradine The metabolism of Ivabradine can be decreased when combined with Fluconazole.
Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Fluconazole.
Losartan The serum concentration of E3174, an active metabolite of Losartan, can be decreased when used in combination with Fluconazole.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Fluconazole.
Lurasidone The metabolism of Lurasidone can be decreased when combined with Fluconazole.
Nevirapine The serum concentration of Nevirapine can be increased when it is combined with Fluconazole.
Olaparib The metabolism of Olaparib can be decreased when combined with Fluconazole.
Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Fluconazole.
Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Fluconazole.
Prednisone The serum concentration of Prednisone can be increased when it is combined with Fluconazole.
Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Fluconazole.
Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Fluconazole.
Ruxolitinib The serum concentration of Ruxolitinib can be increased when it is combined with Fluconazole.
Simvastatin The metabolism of Simvastatin can be decreased when combined with Fluconazole.
Sonidegib The metabolism of Sonidegib can be decreased when combined with Fluconazole.
Tipranavir The serum concentration of Tipranavir can be increased when it is combined with Fluconazole.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Fluconazole.
Voriconazole The metabolism of Voriconazole can be decreased when combined with Fluconazole.
Zidovudine The metabolism of Zidovudine can be decreased when combined with Fluconazole.
Avanafil The metabolism of Avanafil can be decreased when combined with Fluconazole.
Eplerenone The metabolism of Eplerenone can be decreased when combined with Fluconazole.
Erythromycin Fluconazole may increase the QTc-prolonging and arrhythmogenic activities of Erythromycin.
Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Fluconazole.
Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Fluconazole.
Pantoprazole The metabolism of Pantoprazole can be decreased when combined with Fluconazole.
Omeprazole The metabolism of Omeprazole can be decreased when combined with Fluconazole.
Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Fluconazole.
Esomeprazole The metabolism of Esomeprazole can be decreased when combined with Fluconazole.
Rabeprazole The metabolism of Rabeprazole can be decreased when combined with Fluconazole.
Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Fluconazole.
Dexrabeprazole The metabolism of Dexrabeprazole can be decreased when combined with Fluconazole.
Ilaprazole The metabolism of Ilaprazole can be decreased when combined with Fluconazole.
Colchicine The serum concentration of Colchicine can be increased when it is combined with Fluconazole.
Fentanyl The metabolism of Fentanyl can be decreased when combined with Fluconazole.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Fluconazole.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Fluconazole.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Fluconazole.
Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Fluconazole.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Fluconazole.
Glimepiride The serum concentration of Glimepiride can be increased when it is combined with Fluconazole.
Acetohexamide The serum concentration of Acetohexamide can be increased when it is combined with Fluconazole.
Chlorpropamide The serum concentration of Chlorpropamide can be increased when it is combined with Fluconazole.
Tolazamide The serum concentration of Tolazamide can be increased when it is combined with Fluconazole.
Glyburide The serum concentration of Glyburide can be increased when it is combined with Fluconazole.
Glipizide The serum concentration of Glipizide can be increased when it is combined with Fluconazole.
Gliclazide The serum concentration of Gliclazide can be increased when it is combined with Fluconazole.
Tolbutamide The serum concentration of Tolbutamide can be increased when it is combined with Fluconazole.
Gliquidone The serum concentration of Gliquidone can be increased when it is combined with Fluconazole.
Glisoxepide The serum concentration of Glisoxepide can be increased when it is combined with Fluconazole.
Glibornuride The serum concentration of Glibornuride can be increased when it is combined with Fluconazole.
Carbutamide The serum concentration of Carbutamide can be increased when it is combined with Fluconazole.
Metahexamide The serum concentration of Metahexamide can be increased when it is combined with Fluconazole.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Fluconazole.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Fluconazole.
Sucralfate Sucralfate can cause a decrease in the absorption of Fluconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Fluconazole.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Fluconazole.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Fluconazole.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Fluconazole.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Fluconazole.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Fluconazole.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Fluconazole.
Vincristine The excretion of Vincristine can be decreased when combined with Fluconazole.
Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Fluconazole.
Leuprolide The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Goserelin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Moxifloxacin.
Sulpiride The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Sulpiride.
Nimodipine The metabolism of Nimodipine can be decreased when combined with Fluconazole.
Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Fluconazole.
Droperidol The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Droperidol.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fluconazole.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Fluorouracil.
Perflutren The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Perflutren.
Atropine The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Atropine.
Efavirenz The metabolism of Efavirenz can be decreased when combined with Fluconazole.
Adenosine The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Adenosine.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Gadobenic acid.

Target Protein

Lanosterol 14-alpha demethylase ERG11

Referensi & Sumber

Artikel (PubMed)
  • PMID: 29377368
    Bongomin F, Oladele RO, Gago S, Moore CB, Richardson MD: A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses. 2018 May;61(5):290-297. doi: 10.1111/myc.12747. Epub 2018 Feb 14.
  • PMID: 18476045
    Hollier LM, Cox SM: Fluconazole (Diflucan). Infect Dis Obstet Gynecol. 1995;3(6):222-5. doi: 10.1155/S1064744995000676.
  • PMID: 25843556
    Allen D, Wilson D, Drew R, Perfect J: Azole antifungals: 35 years of invasive fungal infection management. Expert Rev Anti Infect Ther. 2015 Jun;13(6):787-98. doi: 10.1586/14787210.2015.1032939. Epub 2015 Apr 5.
  • PMID: 18366001
    Zonios DI, Bennett JE: Update on azole antifungals. Semin Respir Crit Care Med. 2008 Apr;29(2):198-210. doi: 10.1055/s-2008-1063858.
  • PMID: 21803962
    Lewis RE: Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011 Aug;86(8):805-17. doi: 10.4065/mcp.2011.0247.
  • PMID: 29279242
    Thamban Chandrika N, Shrestha SK, Ngo HX, Howard KC, Garneau-Tsodikova S: Novel fluconazole derivatives with promising antifungal activity. Bioorg Med Chem. 2018 Feb 1;26(3):573-580. doi: 10.1016/j.bmc.2017.12.018. Epub 2017 Dec 17.
  • PMID: 28814889
    Berkow EL, Lockhart SR: Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist. 2017 Jul 31;10:237-245. doi: 10.2147/IDR.S118892. eCollection 2017.
  • PMID: 10515900
    Ghannoum MA, Rice LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999 Oct;12(4):501-17.
Menampilkan 8 dari 24 artikel.

Contoh Produk & Brand

Produk: 490 • International brands: 7
Produk
  • Act Fluconazole
    Tablet • 50 mg • Oral • Canada • Approved
  • Act Fluconazole
    Tablet • 100 mg • Oral • Canada • Approved
  • Apo-fluconazole
    Tablet • 200 mg • Oral • Canada • Generic • Approved
  • Apo-fluconazole
    Tablet • 50 mg • Oral • Canada • Generic • Approved
  • Apo-fluconazole
    Tablet • 100 mg • Oral • Canada • Generic • Approved
  • Apo-fluconazole-150
    Capsule • 150 mg • Oral • Canada • Generic • OTC • Approved
  • Bio-fluconazole
    Capsule • 150 mg • Oral • Canada • Generic • OTC • Approved
  • Canesoral
    Capsule • 150 mg • Oral • Canada • OTC • Approved
Menampilkan 8 dari 490 produk.
International Brands
  • Elazor
  • Flucazol
  • Flucostat
  • Flunizol
  • Pritenzol
  • Trican
  • Triflucan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul